Corresponding Author: Carol M. Mangione, MD, MSPH, David Geffen School of Medicine, University of California, Los Angeles, 10940 Wilshire Blvd, Ste 700, Los Angeles, CA 90024 (firstname.lastname@example.org).
Accepted for Publication: September 26, 2022.
The US Preventive Services Task Force (USPSTF) Members: Carol M. Mangione, MD, MSPH; Michael J. Barry, MD; Wanda K. Nicholson, MD, MPH, MBA; Michael Cabana, MD, MA, MPH; Aaron B. Caughey, MD, PhD; David Chelmow, MD; Tumaini Rucker Coker, MD, MBA; Esa M. Davis, MD, MPH; Katrina E. Donahue, MD, MPH; Carlos Roberto Jaén, MD, PhD, MS; Martha Kubik, PhD, RN; Li Li, MD, PhD, MPH; Gbenga Ogedegbe, MD, MPH; Lori Pbert, PhD; John M. Ruiz, PhD; James Stevermer, MD, MSPH; John B. Wong, MD.
Affiliations of The US Preventive Services Task Force (USPSTF) Members: University of California, Los Angeles (Mangione); Harvard Medical School, Boston, Massachusetts (Barry); University of North Carolina at Chapel Hill (Nicholson, Donahue); Albert Einstein College of Medicine, New York, New York (Cabana); Oregon Health & Science University, Portland (Caughey); Virginia Commonwealth University, Richmond (Chelmow); University of Washington, Seattle (Coker); University of Pittsburgh, Pittsburgh, Pennsylvania (Davis); The University of Texas Health Science Center, San Antonio (Jaén); George Mason University, Fairfax, Virginia (Kubik); University of Virginia, Charlottesville (Li); New York University, New York, New York (Ogedegbe); University of Massachusetts Medical School, Worcester (Pbert); University of Arizona, Tucson (Ruiz); University of Missouri, Columbia (Stevermer); Tufts University School of Medicine, Boston, Massachusetts (Wong).
Author Contributions: Dr Mangione had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The USPSTF members contributed equally to the recommendation statement.
Conflict of Interest Disclosures: Authors followed the policy regarding conflicts of interest described at https://www.uspreventiveservicestaskforce.org/Page/Name/conflict-of-interest-disclosures. All members of the USPSTF receive travel reimbursement and an honorarium for participating in USPSTF meetings.
Funding/Support: The USPSTF is an independent, voluntary body. The US Congress mandates that the Agency for Healthcare Research and Quality (AHRQ) support the operations of the USPSTF.
Role of the Funder/Sponsor: AHRQ staff assisted in the following: development and review of the research plan, commission of the systematic evidence review from an Evidence-based Practice Center, coordination of expert review and public comment of the draft evidence report and draft recommendation statement, and the writing and preparation of the final recommendation statement and its submission for publication. AHRQ staff had no role in the approval of the final recommendation statement or the decision to submit for publication.
Disclaimer: Recommendations made by the USPSTF are independent of the US government. They should not be construed as an official position of AHRQ or the US Department of Health and Human Services.
Additional Contributions: We thank Howard Tracer, MD (AHRQ), who contributed to the writing of the manuscript, and Lisa Nicolella, MA (AHRQ), who assisted with coordination and editing.
Additional Information: The US Preventive Services Task Force (USPSTF) makes recommendations about the effectiveness of specific preventive care services for patients without obvious related signs or symptoms. It bases its recommendations on the evidence of both the benefits and harms of the service and an assessment of the balance. The USPSTF does not consider the costs of providing a service in this assessment. The USPSTF recognizes that clinical decisions involve more considerations than evidence alone. Clinicians should understand the evidence but individualize decision-making to the specific patient or situation. Similarly, the USPSTF notes that policy and coverage decisions involve considerations in addition to the evidence of clinical benefits and harms. Published by JAMA®—Journal of the American Medical Association under arrangement with the Agency for Healthcare Research and Quality (AHRQ). ©2022 AMA and United States Government, as represented by the Secretary of the Department of Health and Human Services (HHS), by assignment from the members of the United States Preventive Services Task Force (USPSTF). All rights reserved.
SD , Gass
M , Hall
et al; STRAW 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause
. 2012;19(4):387-395. doi:10.1097/gme.0b013e31824d8f40PubMedGoogle ScholarCrossref
JE , Chlebowski
RT , Stefanick
et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA
. 2013;310(13):1353-1368. doi:10.1001/jama.2013.278040PubMedGoogle ScholarCrossref
G , Patel
SV , Reddy
S , Rains
C , Coker-Schwimmer
M , Kahwati
L . Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons: An Evidence Review for the US Preventive Services Task Force. Evidence Synthesis No. 222. Agency for Healthcare Research and Quality; 2022. AHRQ publication 22-05294-EF-1.
G , Patel
SV , Reddy
S , Rains
C , Schwimmer
M , Kahwati
L . Hormone therapy for the primary prevention of chronic conditions in postmenopausal persons: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA
. Published November 1, 2022. doi:10.1001/jama.2022.18324Google Scholar
US Preventive Services Task Force. Behavioral counseling interventions to promote a healthy diet and physical activity for cardiovascular disease prevention in adults with cardiovascular risk factors: US Preventive Services Task Force recommendation statement. JAMA
. 2020;324(20):2069-2075. doi:10.1001/jama.2020.21749PubMedGoogle ScholarCrossref
US Preventive Services Task Force. Behavioral counseling to promote a healthful diet and physical activity for cardiovascular disease prevention in adults without cardiovascular risk factors: US Preventive Services Task Force recommendation statement. JAMA
. 2017;318(2):167-174. doi:10.1001/jama.2017.7171PubMedGoogle ScholarCrossref
US Preventive Services Task Force. Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: US Preventive Services Task Force recommendation statement. JAMA
. 2017;318(22):2224-2233. doi:10.1001/jama.2017.18261PubMedGoogle ScholarCrossref
RT , Anderson
GL , Aragaki
et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women’s Health Initiative randomized clinical trials. JAMA
. 2020;324(4):369-380. doi:10.1001/jama.2020.9482PubMedGoogle ScholarCrossref
RL , Aragaki
AK , Chlebowski
et al. Dual-outcome intention-to-treat analyses in the Women’s Health Initiative randomized controlled hormone therapy trials. Am J Epidemiol
. 2020;189(9):972-981. doi:10.1093/aje/kwaa033PubMedGoogle ScholarCrossref
AZ , Chlebowski
RT , Manson
et al; WHI Investigators. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA
. 2011;305(13):1305-1314. doi:10.1001/jama.2011.382PubMedGoogle ScholarCrossref
NB , Cauley
JA , Jackson
et al; Women’s Health Initiative Investigators. No increase in fractures after stopping hormone therapy: results from the Women’s Health Initiative. J Clin Endocrinol Metab
. 2017;102(1):302-308.PubMedGoogle Scholar
KL , Bonds
DE , Rodabough
et al; Women’s Health Initiative Investigators. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women’s Health Initiative Hormone Trial. Diabetologia
. 2004;47(7):1175-1187. doi:10.1007/s00125-004-1448-xPubMedGoogle ScholarCrossref
AM , Herrington
D , Vittinghoff
et al; Heart and Estrogen/progestin Replacement Study. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study: a randomized, double-blind, placebo-controlled trial. Ann Intern Med
. 2003;138(1):1-9. doi:10.7326/0003-4819-138-1-200301070-00005PubMedGoogle ScholarCrossref
SA , Legault
C , Rapp
et al; WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA
. 2003;289(20):2651-2662. doi:10.1001/jama.289.20.2651PubMedGoogle ScholarCrossref
SA , Legault
C , Kuller
et al; Women’s Health Initiative Memory Study. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study. JAMA
. 2004;291(24):2947-2958. doi:10.1001/jama.291.24.2947PubMedGoogle ScholarCrossref
L ; American College of Obstetricians and Gynecologists. ACOG releases practice bulletin on osteoporosis. Am Fam Physician
. 2013;88(4):269-275.PubMedGoogle Scholar